Wild-type EVI1 with S436 available for phosphorylation, but not non-phosphorylatable EVI1-S436A, conferred hematopoietic progenitor cell self-renewal and was associated with significantly higher organized transcriptional patterns.
[Cell Death & Disease]
1254621 ANNRU2LA items 1 apa default asc 1
Paredes, R., Kelly, J. R., Geary, B., Almarzouq, B., Schneider, M., Pearson, S., Narayanan, P., Williamson, A., Lovell, S. C., Wiseman, D. H., Chadwick, J. A., Jones, N. J., Kustikova, O., Schambach, A., Garner, T., Amaral, F. M. R., Pierce, A., Stevens, A., Somervaille, T. C. P., … Meyer, S. (2020). EVI1 phosphorylation at S436 regulates interactions with CtBP1 and DNMT3A and promotes self-renewal. Cell Death & Disease, 11(10), 1–14. https://doi.org/10.1038/s41419-020-03099-0 Cite
Investigators showed interlukine-17 receptor B (IL-17RB) expression was positively correlated with mucin 1 (MUC1) and MUC4 expression in pancreatic cancer cells and tumor tissue.
6445212 3XX6MUGJ items 1 apa default asc 1
Tsai, L.-H., Hsu, K.-W., Chiang, C.-M., Yang, H.-J., Liu, Y.-H., Yang, S.-F., Peng, P.-H., Cheng, W.-C., & Wu, H.-H. (2020). Targeting interleukin-17 receptor B enhances gemcitabine sensitivity through downregulation of mucins in pancreatic cancer. Scientific Reports, 10(1), 17817. https://doi.org/10.1038/s41598-020-73659-z Cite
Investigators showed that WNT11-FZD7-DAAM1 activated Rho-ROCK1/2-Myosin II and played a crucial role in regulating tumour-initiating potential, local invasion and distant metastasis formation.
6445212 WBVXBRXR items 1 apa default asc 1
Rodriguez-Hernandez, I., Maiques, O., Kohlhammer, L., Cantelli, G., Perdrix-Rosell, A., Monger, J., Fanshawe, B., Bridgeman, V. L., Karagiannis, S. N., Penin, R. M., Marcolval, J., Marti, R. M., Matias-Guiu, X., Fruhwirth, G. O., Orgaz, J. L., Malanchi, I., & Sanz-Moreno, V. (2020). WNT11-FZD7-DAAM1 signalling supports tumour initiating abilities and melanoma amoeboid invasion. Nature Communications, 11(1), 5315. https://doi.org/10.1038/s41467-020-18951-2 Cite
Investigators describe a 2D in vitro system for long-term enrichment of pancreatic cancer stem cells (CSCs) that was amenable to biological and CSC-specific studies.
6445212 EWUYP4B7 items 1 apa default asc 1
Valle, S., Alcalá, S., Martin-Hijano, L., Cabezas-Sáinz, P., Navarro, D., Muñoz, E. R., Yuste, L., Tiwary, K., Walter, K., Ruiz-Cañas, L., Alonso-Nocelo, M., Rubiolo, J. A., González-Arnay, E., Heeschen, C., Garcia-Bermejo, L., Hermann, P. C., Sánchez, L., Sancho, P., Fernández-Moreno, M. Á., & Sainz, B. (2020). Exploiting oxidative phosphorylation to promote the stem and immunoevasive properties of pancreatic cancer stem cells. Nature Communications, 11(1), 5265. https://doi.org/10.1038/s41467-020-18954-z Cite
Several in vitro and in vivo mechanisms involved in pancreatic cancer (PDAC) metastases were investigated following treatment with P-AscH−. Serum from PDAC patients in clinical trials with P-AscH− were tested for the presence and quantity of circulating tumor cell-derived nucleases.
6445212 JX7RYHDM items 1 apa default asc 1
Researchers identified Tenascin C (TNC) to be upregulated and secreted in mesenchymal glioblastoma subtype with high NF-κB signaling activity. Silencing TNC decreased proliferation, migration and suppresses self-renewal of glioma stem cells.
Scientists discuss molecular maintenance in leukemia stem cells in chronic myeloid leukemia and provide a more in-depth discussion of the dual-specificity kinase DYRK2, which has been identified as a novel actionable checkpoint in a critical leukemic network.
[Experimental and Molecular Medicine]
Merck announced that the FDA has approved an expanded label for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.
[Merck & Co., Inc.]
6445212 nan items 1 apa default asc 1
Despite several efforts, transcriptomic and genomic classifications have remained merely theoretic and most of the patients are being treated with chemotherapy. Driver alterations in potentially targetable genes, including PIK3CA and AKT, have been identified across triple negative breast cancer subtypes, prompting the implementation of biomarker-driven therapeutic approaches.
[npj breast cancer]
6445212 UTL7INB7 items 1 apa default asc 1
Investigators found that active targeting nanoparticles displayed a superior DNA damage capability via enhanced-interactions with DNA and a significantly stronger effect in reducing cancer stem cell-like property of triple negative breast cancer cells, compared to conventional cisplatin and miriplatin.
[Journal of Controlled Release]
6445212 W89EEME9 items 1 apa default asc 1
Li, Y., Qian, D., Lin, H.-P., Xie, J., Yang, P., Maddy, D., Xiao, Y., Huang, X., Wang, Z., & Yang, C. (2020). Nanoparticle-delivered miriplatin ultrasmall dots suppress triple negative breast cancer lung metastasis by targeting circulating tumor cells. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2020.10.015 Cite
The authors observed that ras-association domain family protein1 isoform A (RASSF1A) expression inhibited the malignant phenotypes of nasopharyngeal carcinoma (NPC) cells. Stable silencing of RASSF1A in NPC cell lines induced self-renewal properties and tumorigenicity in vivo/in vitro and the acquisition of an invasive phenotype in vitro.
[Cell Death & Disease]
6445212 FNF2EWGE items 1 apa default asc 1
Liang, Y.-Y., Deng, X.-B., Lin, X.-T., Jiang, L.-L., Huang, X.-T., Mo, Z.-W., Yuan, Y.-W., & Teh, M.-T. (2020). RASSF1A inhibits PDGFB-driven malignant phenotypes of nasopharyngeal carcinoma cells in a YAP1-dependent manner. Cell Death & Disease, 11(10), 1–12. https://doi.org/10.1038/s41419-020-03054-z Cite